The Journal of Clinical Investigation (Sep 2023)

Hemolysis dictates monocyte differentiation via two distinct pathways in sickle cell disease vaso-occlusion

  • Yunfeng Liu,
  • Shan Su,
  • Sarah Shayo,
  • Weili Bao,
  • Mouli Pal,
  • Kai Dou,
  • Patricia A. Shi,
  • Banu Aygun,
  • Sally Campbell-Lee,
  • Cheryl A. Lobo,
  • Avital Mendelson,
  • Xiuli An,
  • Deepa Manwani,
  • Hui Zhong,
  • Karina Yazdanbakhsh

Journal volume & issue
Vol. 133, no. 18

Abstract

Read online

Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by painful vaso-occlusive crises (VOC) and chronic hemolysis. The mononuclear phagocyte system is pivotal to SCD pathophysiology, but the mechanisms governing monocyte/macrophage differentiation remain unknown. This study examined the influence of hemolysis on circulating monocyte trajectories in SCD. We discovered that hemolysis stimulated CSF-1 production, partly by endothelial cells via Nrf2, promoting classical monocyte (CMo) differentiation into blood patrolling monocytes (PMo) in SCD mice. However, hemolysis also upregulated CCL-2 through IFN-I, inducing CMo transmigration and differentiation into tissue monocyte–derived macrophages. Blocking CMo transmigration by anti–P selectin antibody in SCD mice increased circulating PMo, corroborating that CMo-to–tissue macrophage differentiation occurs at the expense of CMo-to–blood PMo differentiation. We observed a positive correlation between plasma CSF-1/CCL-2 ratios and blood PMo levels in patients with SCD, underscoring the clinical significance of these two opposing factors in monocyte differentiation. Combined treatment with CSF-1 and anti–P selectin antibody more effectively increased PMo numbers and reduced stasis compared with single-agent therapies in SCD mice. Altogether, these data indicate that monocyte fates are regulated by the balance between two heme pathways, Nrf2/CSF-1 and IFN-I/CCL-2, and suggest that the CSF-1/CCL-2 ratio may present a diagnostic and therapeutic target in SCD.

Keywords